Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-FOXP3 antisense oligonucleotide AZD8701

An antisense oligonucleotide (ASO) targeting the Forkhead Box P3 (FOXP3) mRNA, with potential immunomodulating and antineoplastic activities. Upon administration, anti-FOXP3 ASO AZD8701 blocks the translation of the FOXP3 protein. Reduction of FOXP3 levels may lessen the immunosuppressive functions of regulatory T cells (Tregs). This may lead to an enhanced immune response and antitumor activity. FOXP3, a transcription factor, plays an important role in the functioning of immunosuppressive Tregs. Tregs are overexpressed in various cancers and are associated with poor response to immune checkpoint inhibitors and poor survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-FOXP3 ASO AZD8701
FOXP3-targeting antisense oligonucleotide AZD8701
Code name:AZD 8701
AZD-8701
AZD8701
ION 736
ION-736
ION736
IONIS-AZ7-2.5Rx
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search